GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nika Pharmaceuticals Inc (OTCPK:NIKA) » Definitions » Cash-to-Debt

NIKA (Nika Pharmaceuticals) Cash-to-Debt : No Debt (1) (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Nika Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nika Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2024 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nika Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Nika Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

NIKA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18   Med: No Debt   Max: No Debt
Current: No Debt

During the past 5 years, Nika Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.18. And the median was No Debt.

NIKA's Cash-to-Debt is ranked better than
99.71% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs NIKA: No Debt

Nika Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Nika Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nika Pharmaceuticals Cash-to-Debt Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
N/A 0.18 N/A No Debt No Debt

Nika Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A No Debt No Debt No Debt No Debt

Competitive Comparison of Nika Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Nika Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nika Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nika Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nika Pharmaceuticals's Cash-to-Debt falls into.



Nika Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nika Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Nika Pharmaceuticals had no debt (1).

Nika Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Nika Pharmaceuticals had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nika Pharmaceuticals  (OTCPK:NIKA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Nika Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nika Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Nika Pharmaceuticals Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution for the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.